LivaNova (NASDAQ:LIVN - Get Free Report) is scheduled to be announcing its earnings results before the market opens on Wednesday, October 30th. Analysts expect the company to announce earnings of $0.71 per share for the quarter. LivaNova has set its FY 2024 guidance at 3.100-3.200 EPS and its FY24 guidance at $3.10-$3.20 EPS.Individual interested in registering for the company's earnings conference call can do so using this link.
LivaNova (NASDAQ:LIVN - Get Free Report) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $0.81 EPS for the quarter, topping analysts' consensus estimates of $0.66 by $0.15. The company had revenue of $318.60 million during the quarter, compared to analyst estimates of $305.05 million. LivaNova had a positive return on equity of 13.77% and a negative net margin of 1.37%. On average, analysts expect LivaNova to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.
LivaNova Stock Performance
Shares of LIVN traded down $0.33 on Wednesday, reaching $53.00. 327,767 shares of the stock traded hands, compared to its average volume of 620,612. The firm has a market cap of $2.87 billion, a price-to-earnings ratio of -88.88 and a beta of 1.00. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.45 and a quick ratio of 2.94. LivaNova has a 12 month low of $42.75 and a 12 month high of $64.47. The stock's 50-day moving average price is $50.12 and its 200-day moving average price is $53.22.
Analysts Set New Price Targets
A number of brokerages have weighed in on LIVN. Needham & Company LLC upped their price target on LivaNova from $72.00 to $75.00 and gave the company a "buy" rating in a research report on Wednesday, July 31st. Robert W. Baird raised LivaNova from a "neutral" rating to an "outperform" rating and boosted their price objective for the stock from $55.00 to $66.00 in a research note on Tuesday, September 17th. The Goldman Sachs Group started coverage on LivaNova in a research note on Friday, October 4th. They issued a "buy" rating and a $65.00 target price on the stock. Stifel Nicolaus increased their target price on LivaNova from $70.00 to $72.00 and gave the company a "buy" rating in a research note on Thursday, July 25th. Finally, Baird R W raised LivaNova from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, September 17th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, LivaNova currently has an average rating of "Buy" and a consensus target price of $69.83.
Read Our Latest Stock Analysis on LivaNova
About LivaNova
(
Get Free Report)
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
Recommended Stories
Before you consider LivaNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LivaNova wasn't on the list.
While LivaNova currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
